Serum levels of VEGF and bFGF in hypoxic patients with exacerbated COPD

European Cytokine Network

Volumn 21, Issue 2, 2010, Pages 92-98

  Pavlisa, Gordana ^a   Pavlisa, Goran ^b   Kusec, Vesna ^b   Kolonic, Slobodanka Ostojic ^c   Markovic, Asja Stipic ^d   Jaksic, Branimir ^c  

^a University Hospital for Lung Diseases Jordanovac   (Croatia)

^b KBC Zagreb   (Croatia)

^c University of Zagreb   (Croatia)

^d Croatian Academy of Medical Sciences   (Croatia)

Author keywords

bFGF; COPD; Hypoxia; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTERIAL OXYGEN TENSION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPOXIA; LEUKOCYTE; MALE; MULTIVARIATE ANALYSIS; PH; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; TISSUE OXYGENATION;

AGED; ANOXIA; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953909546     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2010.0193     Document Type: Article

References (36)

1. Gleadle JM, Ratcliffe PJ. Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. Blood 1997; 89: 503.
2. Pavlisa G, Vrbanic V, Kusec V, Jaksic B. Erythropoietin response after correction of severe hypoxaemia due to acute respiratory failure in chronic obstructive pulmonary disease patients. Clin Sci (Lond) 2004; 106: 43.
3. Bussolino F, Albini A, Camussi G, et al. Role of soluble mediators in angiogenesis. Eur J Cancer 1996; 32A: 2401.
4. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029.
5. Klagsbrun M. The fibroblast growth factor family: structural and biological properties. Prog Growth Factor Res 1989; 1: 207.
6. Malamitsi-Puchner A, Tziotis J, Tsonou A, Protonotariou E Sarandakou ACreatsas G. Basic fibroblast growth factor: serum levels in the female. Growth Factors 2000; 17: 215.
7. Bussolino F, Albini A, Camussi G, et al. Hypoxic responses of vascular cells. Chest 1998; 114: 25S.
8. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistle-thwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 2000; 342: 626.
9. Detillieux KA, Cattini PA, Kardami E. Beyond angiogenesis: the cardioprotective potential of fibroblast growth factor-2. Can J Physiol Pharmacol 2004; 82: 1044. (Pubitemid 40343640)
10. Imagawa S, Yamaguchi Y, Higuchi M, Neichi T, Hasegawa Y, Mukai HY. Levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea-hypopnea syndrome. Blood 2001; 98: 1255.
11. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256.
12. Gustafsson T, Puntschart A, Sundberg CJ, Jansson E. Related expression of vascular endothelial growth factor and hypoxia-inducible factor-1 mRNAs in human skeletal muscle. Acta Physiol Scand 1999; 165: 335.
13. Hayashi T, Abe K, Suzuki H, Itoyama Y. Rapid induction of vascular endothelial growth factor gene expression after transient middle cerebral artery occlusion in rats. Stroke 1997; 28: 2039.
14. Hochberg I, Hoffman A, Levy AP. Regulation of VEGF in diabetic patients with critical limb ischemia. Ann Vasc Surg 2001; 15: 388.
15. Valipour A, Schreder M, Wolzt M, et al. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci (Lond) 2008; 115: 225.
16. Aldonyte R, Eriksson S, Piitulainen E, Wallmark A Janciauskiene S. Analysis of systemic biomarkers in COPD patients. COPD 2004; 1: 155.
17. Kierszniewska-Stepie D, Pietras T. G¢rski P, Stepien H. Serum vascular endothelial growth factor and its receptor level in patients with chronic obstructive pulmonary disease. Eur Cytokine Netw 2006; 17: 75.
18. Yin R, Feng J, Yao Z. Dynamic changes of serum vascular endothelial growth factor levels in a rat myocardial infarction model. Chin Med Sci J 2000; 15: 154.
19. Alatas F, Alatas O, Metintas M, Ozarslan A, Erginel S, Yildirim H. Vascular endothelial growth factor levels in active pulmonary tuberculosis. Chest 2004; 125: 2156.
20. Yano K, Liaw PC, Mullington JM, et al. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 2006; 203: 1447.
21. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003; 6: 283.
22. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996; 271: 736.
23. D'silva L. Cook RJ, Allen CJ, Hargreave FE, Parameswaran K. Changing pattern of sputum cell counts during successive exacerbations of airway disease. Respir Med 2007; 101: 2217-20.
24. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84: 210.
25. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 2001; 34: s50.
26. Koehne P, Willam C, Strauss E, Schindler R, Eckardt KU. B-hrer C. Lack of hypoxic stimulation of VEGF secretion from neutrophils and platelets. Am J Physiol Heart Circ Physiol 2000; 279: H817.
27. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000; 106: 1311.
28. Kanazawa H, Asai K, Nomura S. Vascular endothelial growth factor as a non-invasive marker of pulmonary vascular remodeling in patients with bronchitis-type of COPD. Respir Res 2007; 8: 22.
29. Olfert IM, Breen EC, Mathieu-Costello O, Wagner PD. Skeletal muscle capillarity and angiogenic mRNA levels after exercise training in normoxia and chronic hypoxia. J Appl Physiol 2001; 91: 1176.
30. Panutsopulos D, Zafiropoulos A, Krambovitis E, Kochiadakis GE, Igoumenidis NE, Spandidos DA. Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression. J Transl Med 2003; 1: 6.
31. Porta C, Imarisio I, De Amici M, et al. Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. Oncol Rep 2005; 13: 689.
32. Ganat Y, Soni S, Chacon M, Schwartz ML, Vaccarino FM. Chronic hypoxia up-regulates fibroblast growth factor ligands in the perinatal brain and induces fibroblast growth factor-responsive radial glial cells in the sub-ependymal zone. Neuroscience 2002; 112: 977.
33. Larsson A. Sköldenberg E, Ericson H. Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis 2002; 5: 107.
34. Stompór T, Zdzienicka A, Motyka M, Dembińska-Kieć A, Davies SJ, Sulowicz W. Selected growth factors in peritoneal dialysis: their relationship to markers of inflammation, dialysis adequacy, residual renal function, and peritoneal membrane transport. Perit Dial Int 2002; 22: 670.
35. Bucala R, Ritchlin C, Winchester R, Cerami A. Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J Exp Med 1991; 173: 569.
36. Jee SH, Chu CY, Chiu HC, Huang YL, Tsai WL, Liao YH. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Invest Dermatol 2004; 123: 1169.